Salvage Therapy for Recurrent Prostate Cancer: After Surgery & Radiation

What is biochemical recurrence (BCR)?

Biochemical recurrence (BCR) is a rising PSA after primary curative treatment (surgery or radiation) without evidence of metastatic disease on imaging. Definitions differ:

• After radical prostatectomy: Two consecutive PSA rises >0.2 ng/mL (AUA definition)
• After radiation therapy: Rise of 2.0 ng/mL above the nadir (Phoenix criteria)

BCR does not always lead to clinical recurrence. However, salvage therapy can improve outcomes in select patients.

Salvage radiation after radical prostatectomy

Salvage radiation therapy (SRT) is the most common salvage treatment for BCR after prostatectomy.

Indications:

• PSA >0.2 ng/mL and rising
• PSA doubling time <12 months (worse prognosis)
• PSMA PET negative for distant metastases
• No prior pelvic radiation

Timing:

• Earlier is better – treat at PSA <0.5 ng/mL for best outcomes
• Delaying SRT reduces efficacy

Regimen:

• Dose: 64-72 Gy to the prostate bed
• Target: prostate bed (sometimes whole pelvis if high-risk features)
• Hormone therapy: Added for high-risk patients (Gleason 8+, PSA >1.0, PSADT <6 months)

Outcomes:

• 5-year biochemical progression-free survival: 50-70%
• Better outcomes with PSA <0.5 ng/mL at SRT

Salvage cryotherapy after radiation failure

Salvage cryotherapy (cryoablation) is an option for men with biopsy-proven local recurrence after primary radiation therapy (external beam or brachytherapy).

Indications:

• Biopsy-proven local recurrence (no distant metastases)
• PSA rise after radiation (Phoenix criteria)
• Life expectancy >10 years
• No prior salvage therapy

Outcomes:

• 5-year biochemical recurrence-free survival: 40-60%
• 5-year metastasis-free survival: 70-80%

Complications (higher than primary cryotherapy):

• Urinary incontinence: 10-20%
• Erectile dysfunction: 50-80%
• Rectourethral fistula: 1-5%

Salvage HIFU after radiation failure

Salvage High-Intensity Focused Ultrasound (HIFU) is an emerging option for local recurrence after radiation.

Indications:

• Biopsy-proven local recurrence
• No evidence of metastatic disease
• Prostate size <40-50 mL (preferred)

Outcomes:

• 5-year biochemical recurrence-free survival: 40-60%
• Similar to salvage cryotherapy

Complications:

• Urinary incontinence: 10-20%
• Erectile dysfunction: 50-70%
• Rectourethral fistula: 1-3%

Salvage radical prostatectomy after radiation

Salvage radical prostatectomy (SRP) is the most invasive salvage option for local recurrence after radiation. It is rarely performed due to high complication rates.

Indications:

• Biopsy-proven local recurrence
• Young, healthy patient with long life expectancy
• No evidence of metastatic disease
• Patient refuses or is not candidate for salvage cryotherapy/HIFU

Outcomes:

• 5-year biochemical recurrence-free survival: 40-60%
• 5-year cancer-specific survival: 80-90%

Complications (high):

• Urinary incontinence: 30-50%
• Erectile dysfunction: 80-90%
• Rectal injury/fistula: 5-10%
• Anastomotic stricture: 10-20%

Salvage lymph node dissection for nodal recurrence

For men with isolated lymph node recurrence (N1) detected on PSMA PET, salvage lymph node dissection (LND) may be considered.

Indications:

• PSMA PET shows limited (≤3) lymph node metastases
• No distant metastases
• Good surgical candidate

Outcomes:

• PSA response: 50-70%
• 5-year biochemical recurrence-free survival: 20-40%

Complications:

• Lymphocele (5-10%)
• Lymphedema (2-5%)
• Nerve injury (2-5%)

Systemic therapy for BCR – ADT, enzalutamide, apalutamide

For men with BCR who are not candidates for local salvage therapy or have high-risk features, systemic therapy is used.

Options:

• ADT (androgen deprivation therapy): Traditional approach for high-risk BCR (PSA doubling time <6-12 months)
• Enzalutamide (Xtandi): EMBARK trial showed improved metastasis-free survival in high-risk BCR (PSADT <9 months)
• Apalutamide (Erleada): Also studied in BCR
• Darolutamide (Nubeqa): Emerging option

Indications for systemic therapy:

• PSA doubling time <6-12 months
• High Gleason score (8-10) at diagnosis
• Short time to BCR (<18-24 months after primary treatment)
• Not candidate for salvage radiation or focal therapy

Outcomes and complications

Salvage therapy outcomes vary by modality and patient selection:

• Salvage radiation (post-prostatectomy): 5-year BCR-free survival 50-70%; complications: mild (incontinence 5-10%, bowel 5-10%)
• Salvage cryotherapy/HIFU (post-radiation): 5-year BCR-free survival 40-60%; complications: moderate (incontinence 10-20%, ED 50-80%, fistula 1-5%)
• Salvage prostatectomy (post-radiation): 5-year BCR-free survival 40-60%; complications: high (incontinence 30-50%, ED 80-90%, fistula 5-10%)

Interactive FAQ – Salvage therapy for recurrent prostate cancer

---

Disclaimer: This information is for educational purposes and intended for clinicians and researchers. Salvage therapy decisions should be individualised.